The pros and cons of interferons for oncolytic virotherapy
- 1 December 2020
- journal article
- review article
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 56, 49-58
Abstract
No abstract availableKeywords
Funding Information
- Institut Du Cancer de Montréal
- Fonds de Recherche Quebec-Santé
This publication has 154 references indexed in Scilit:
- Plasmacytoid dendritic cells control T-cell response to chronic viral infectionProceedings of the National Academy of Sciences, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Recruited inflammatory monocytes stimulate antiviral Th1 immunity in infected tissueProceedings of the National Academy of Sciences, 2010
- Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapyCancer Gene Therapy, 2010
- Anticancer activity of oncolytic adenovirus vector armed with IFN-α and ADP is enhanced by pharmacologically controlled expression of TRAILCancer Gene Therapy, 2007
- Induction of MxA Gene Expression by Influenza A Virus Requires Type I or Type III Interferon SignalingJournal of Virology, 2007
- Dendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15Immunity, 2007
- Inhibition of Retinoic Acid-Inducible Gene I-Mediated Induction of Beta Interferon by the NS1 Protein of Influenza A VirusJournal of Virology, 2007
- Cross-priming of CD8+ T cells stimulated by virus-induced type I interferonNature Immunology, 2003
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002